Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is to see if combining bevacizumab with idarubicin and cytarabine works
better in treating patients who have blast phase chronic myelogenous leukemia. Monoclonal
antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the
ability of cancer cells to grow and spread. Others find cancer cells and help kill them or
deliver cancer-killing substances to them. Drugs used in chemotherapy, such as idarubicin and
cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or
die. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment
for blast phase chronic myelogenous leukemia